Genflow Biosciences to hold AGM on 29 June 2026

GENF

Genflow Biosciences Plc (LON:GENF)(OTCQB:GENFF), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, has announced that it will hold its Annual General Meeting (AGM) at 11am on Monday 29 June 2026 at One Heddon Street, London, W1B 4BD.

The Notice of the AGM and Form of Proxy will shortly be available on the Company’s website, www.genflowbio.com, and have, where applicable, been posted to shareholders. Further details of the arrangements for this year’s AGM are set out in the Notice.

As announced on 30 April 2026, the Company’s Annual Report and Accounts for the year ended 31 December 2025 are also available on the website and have, where applicable, also been posted to shareholders.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Genflow Biosciences to hold AGM on 29 June 2026

Genflow Biosciences Plc will hold its Annual General Meeting at 11am on Monday 29 June 2026 at One Heddon Street, London. The Notice of AGM, Form of Proxy, and 2025 Annual Report are available on the company’s website.

Healthspan takes centre stage in the longevity market

Longevity is moving beyond promises of longer life as consumers focus on healthspan, prevention and practical ways to age better.

MASH creates a clearer investment case in liver disease

MASH is becoming a clearer healthcare investment theme as liver disease, metabolic risk and emerging treatment options converge.

Pet healthspan focus opens a clearer senior care opportunity

Senior pet wellness is gaining relevance as owners focus on helping dogs and cats live better, not just longer.

Healthspan moves up the investor agenda

Healthspan is becoming a clearer investor theme as ageing markets shift towards prevention, function and healthier later-life years.

Genflow adds delivery expertise through fully funded Acuitas deal

Genflow Biosciences has secured a fully funded delivery collaboration with Acuitas Therapeutics, giving investors a clearer view of how the company plans to advance its SIRT6 gene therapy platform.

Search